ASPEN PHARMACARE HOLDINGS LIMITED - SA Competition Commissions Decision Not To Refer Complaint About Aspen

SA Competition Commission’s Decision Not To Refer Complaint About Aspen

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen Holdings" or "the Company")


SA COMPETITION COMMISSION’S DECISION NOT TO REFER COMPLAINT ABOUT ASPEN

Aspen welcomes the South African Competition Commission’s (“Commission”) decision to drop its
investigation of Aspen for suspected abuse of dominance and excessive pricing on the basis that,

1.    an excessive pricing case cannot be sustained against Aspen; and
2.    the Commission’s investigation revealed that the revenues attributable to Myleran, Alkeran
      and Leukeran in South Africa are very low as they are at the end of their life cycle and these
      products are prescribed for very few patients.

Mr Stephen Saad, the Group Chief Executive of Aspen, thanked Mr Tembinkosi Bonakele, the
Commissioner of the Commission, and the investigating team for the expeditious and co-operative
manner in which the investigation was undertaken and expressed his pleasure with the
Commission’s decision.

Durban

4 October 2017



Sponsor:

Investec Bank Limited



About Aspen

Aspen has a proud heritage dating back more than 160 years and is committed to sustaining life and
promoting healthcare through increasing access to its high quality affordable medicines and
products.

As a leading global player in specialty, branded and generic pharmaceuticals, Aspen has an extensive
basket of products that provide treatment for a broad spectrum of acute and chronic conditions
experienced through all stages of life. The Group continues to increase the number of lives
benefitting from its products, reaching more than 150 countries. In line with the Group’s
commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics,
high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the
highest focus based on materiality and future potential.

Aspen has a strong presence in both emerging and developed countries with more than 60
established business operations in approximately 50 countries.
Aspen holds international manufacturing approvals from some of the most stringent global
regulatory agencies including the US FDA, TGA and EMA. Aspen’s manufacturing capabilities are
scaleable to demand and cover a wide variety of product-types including oral solid dose, liquids,
semi-solids, steriles, biologicals, APIs and infant nutritionals.

Aspen, with a market capitalisation of approximately $10 billion, is the largest pharmaceutical
company listed on the JSE Limited (share code: APN) and ranks amongst the top 20 listed companies
on this exchange. For more information visit: http://www.aspenpharma.com/

Date: 04/10/2017 02:49:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.